Payment overview · 2025
General Payments
$379.72
20 reported records · 9 companies
Healthcare provider profile · identity verified
Rupert Dyer, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · DAWSON, GA · NPI 1922119650
Verified facts
What the public records show
CMS Open Payments records show Rupert Dyer, D.O. received $379.72 in general payments during 2025 across 20 reported records.
AstraZeneca Pharmaceuticals LP accounted for 25.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Linzess, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Lantus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $94.91 | 25.0% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $74.05 | 19.5% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $66.83 | 17.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $40.43 | 10.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $26.23 | 6.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.41 | 5.9% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $20.78 | 5.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.61 | 5.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.47 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $379.72 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $76.94 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $66.83 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $52.62 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $42.02 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $40.43 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.96 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $26.23 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.43 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.47 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 99 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 135 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 107 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
59 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
90 | 23 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
99 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
30 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
107 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
99 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
135 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 927 | 277 |
| Atorvastatin Calcium | Atorvastatin Calcium | 796 | 259 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 452 | 112 |
| Losartan Potassium | Losartan Potassium | 427 | 132 |
| Fluticasone Propionate | Fluticasone Propionate | 386 | 116 |
| Gabapentin | Gabapentin | 333 | 100 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 304 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 237 | 76 |
| Omeprazole | Omeprazole | 234 | 64 |
| Potassium Chloride | Potassium Chloride | 230 | 83 |
| Metformin Hcl | Metformin Hcl | 223 | 69 |
| Meloxicam | Meloxicam | 215 | 59 |
| Lisinopril | Lisinopril | 208 | 68 |
| Tamsulosin Hcl | Tamsulosin Hcl | 207 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 195 | 53 |
| Levothyroxine Sodium | Levothyroxine Sodium | 189 | 51 |
| Montelukast Sodium | Montelukast Sodium | 187 | 51 |
| Duloxetine Hcl | Duloxetine Hcl | 185 | 52 |
| Furosemide | Furosemide | 171 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 167 | 53 |
| Metformin Hcl Er | Metformin Hcl | 159 | 41 |
| Famotidine | Famotidine | 158 | 52 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 149 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 144 | 42 |
| Ozempic | Semaglutide | 135 | 22 |
| Carvedilol | Carvedilol | 127 | 40 |
| Eliquis | Apixaban | 127 | 37 |
| Januvia | Sitagliptin Phosphate | 125 | 26 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 123 | 29 |
| Diclofenac Sodium | Diclofenac Sodium | 121 | 47 |
| Tradjenta | Linagliptin | 118 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 107 | 19 |
| Atenolol | Atenolol | 104 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 104 | 34 |
| Simvastatin | Simvastatin | 102 | 34 |
| Allopurinol | Allopurinol | 101 | 30 |
| Nifedipine Er | Nifedipine | 101 | 26 |
| Desloratadine | Desloratadine | 99 | 27 |
| Jardiance | Empagliflozin | 99 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 96 | 35 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 94 | 17 |
| Celecoxib | Celecoxib | 92 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 90 | 27 |
| Symbicort | Budesonide/Formoterol Fumarate | 90 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 90 | 28 |
| Glimepiride | Glimepiride | 84 | 23 |
| Sertraline Hcl | Sertraline Hcl | 84 | 25 |
| Azithromycin | Azithromycin | 80 | 66 |
| Prednisone | Prednisone | 79 | 55 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 77 | 20 |
| Trazodone Hcl | Trazodone Hcl | 74 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 71 | 23 |
| Colchicine | Colchicine | 63 | 16 |
| Spironolactone | Spironolactone | 62 | 17 |
| Ketoconazole | Ketoconazole | 60 | 27 |
| Levetiracetam | Levetiracetam | 60 | 11 |
| Farxiga | Dapagliflozin Propanediol | 59 | 14 |
| Tramadol Hcl | Tramadol Hcl | 54 | 19 |
| Azelastine Hcl | Azelastine Hcl | 53 | 17 |
| Mirtazapine | Mirtazapine | 53 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 51 | 15 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 51 | suppressed |
| Naproxen | Naproxen | 51 | 12 |
| Mounjaro | Tirzepatide | 50 | suppressed |
| Pregabalin | Pregabalin | 50 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 48 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 48 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 45 | 13 |
| Methylprednisolone | Methylprednisolone | 45 | 39 |
| Glipizide Er | Glipizide | 44 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 43 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 43 | 28 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 40 | 16 |
| Finasteride | Finasteride | 40 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | 13 |
| Torsemide | Torsemide | 40 | 17 |
| Ventolin Hfa | Albuterol Sulfate | 40 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 37 | suppressed |
| Fluconazole | Fluconazole | 37 | 19 |
| Glipizide | Glipizide | 37 | 11 |
| Enalapril Maleate | Enalapril Maleate | 36 | 11 |
| Ezetimibe | Ezetimibe | 36 | 13 |
| Spiriva Handihaler | Tiotropium Bromide | 36 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 36 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 35 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 35 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | 15 |
| Lovastatin | Lovastatin | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 14 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 32 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 31 | suppressed |
| Myrbetriq | Mirabegron | 31 | 16 |
| Trulicity | Dulaglutide | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 30 | 23 |
| Cephalexin | Cephalexin | 29 | 22 |
| Gemtesa | Vibegron | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 26 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 23 | suppressed |
| Sure Comfort | Syringe-Needle,insulin,0.5 Ml | 23 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 11 |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 13 |
| Brilinta | Ticagrelor | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Calcium Acetate | Calcium Acetate | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | 11 |
| Alprazolam | Alprazolam | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $379.72 · 20 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, GEMTESA, JARDIANCE, LINZESS, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, TZIELD, Wegovy | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error